Please assess the completion status of the following clinical trial:

Trial Title: Clinical Experience of Thalidomide in Thalassemic Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with clinical and genetic diagnosis of β-thalassemia major and intermedia~2. Patients who showed partial response or a decline in response to hydroxyurea~3. Patients who are not the candidates for the bone marrow transplant procedure.~Exclusion Criteria:~1. Married Patients~2. Patients with comorbidities such as liver, cerebrovascular, cardiovascular, or kidney diseases~3. Patients allergic to the drug ingredients~4. Patients with mental disorders~5. Patients who are enrolled in other clinical trials~6. Patients with a history of venous or arterial thrombosis

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination of hydroxyurea and thalidomide (Type: EXPERIMENTAL): Hydroxyurea was continued at a dose of 10-20 mg/kg/day for 6 months and then thalidomide was added orally at a dose of 2-5mg/kg/day for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).